Table of Contents
- Clinical trial overview
- Who the study is for
- What the study is testing
- Study phase and size
- Main endpoint and what it means
- Treatment comparison in the trial
- Important patient terms
Clinical trial overview
The trial listed for Selgantolimod is ANRS HB07 IP-Cure-B, a proof of concept study in chronic hepatitis B.[1] A proof of concept trial is an early study that asks whether a treatment approach may work in people.[1]
This study is interventional, which means the researchers give study treatments and compare the results between groups.[1] The study status is authorised.[1]
Who the study is for
The trial targets people with HBV, which is short for hepatitis B virus infection.[1] The brief summary says the control arm is the standard of care for HBeAg-negative patients with chronic hepatitis B.[1]
HBeAg-negative means a certain hepatitis B blood marker is not present, and this detail matters because treatment plans can differ by patient group.[1]
What the study is testing
The trial is studying the virological effect of stopping nucleos(t)ide analogue treatment, with or without Selgantolimod first.[1] Nucleos(t)ide analogues are common hepatitis B medicines used to keep the virus under control.[1]
According to the study summary, one key question is whether stopping NUC after Selgantolimod treatment can improve outcomes compared with continuing NUC treatment alone for 76 weeks.[1]
The interventions listed in the trial include Selgantolimod and standard hepatitis B medicines such as Vemlidy, Baraclude, and Viread.[1]
Study phase and size
This is a Phase 2 trial.[1] Phase 2 studies usually look more closely at whether a treatment may work while continuing to monitor safety and study design questions.[1]
The planned enrollment is 51 participants.[1] That means the study is relatively small and designed to give early answers about the treatment strategy.[1]
Main endpoint and what it means
The primary endpoint is the percentage of participants with a ≥ 1.0 log10 IU/mL decline in HBsAg at week 76 compared with baseline.[1] Baseline means the starting point before treatment effects are measured.[1]
A drop of 1.0 log10 IU/mL means the HBsAg level falls by a tenfold amount, which is a large change in the virus marker.[1] This endpoint helps researchers judge whether the study treatment plan has a meaningful effect on hepatitis B markers.[1]
Treatment comparison in the trial
The study compares three ideas: continuing NUC treatment for 76 weeks, stopping NUC after Selgantolimod treatment, and stopping NUC without that same study approach.[1] The control arm is continuous NUC treatment, which the summary describes as standard of care for HBeAg-negative chronic hepatitis B patients.[1]
This design helps researchers see whether Selgantolimod changes the chance of lowering HBsAg after treatment is stopped.[1]
Important patient terms
HBV: hepatitis B virus, the virus that causes hepatitis B infection.[1]
HBsAg: a blood marker used to track hepatitis B activity.[1]
NUC: nucleos(t)ide analogue, a type of hepatitis B treatment.[1]
Virological efficacy: how well a treatment affects the virus or virus markers.[1]
Proof of concept: an early study to see if an approach may work.[1]
